Cargando…
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unc...
Autores principales: | Hu, Shangying, Xu, Xiaoqian, Zhu, Fengcai, Hong, Ying, Hu, Yuemei, Zhang, Xun, Pan, Qinjing, Zhang, Wenhua, Zhang, Chengfu, Yang, Xiaoping, Yu, Jiaxi, Zhu, Jiahong, Zhu, Yejiang, Chen, Feng, Zhao, Shuang, Karkada, Naveen, Tang, Haiwen, Bi, Dan, Struyf, Frank, Zhao, Fanghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018349/ https://www.ncbi.nlm.nih.gov/pubmed/33180670 http://dx.doi.org/10.1080/21645515.2020.1829411 |
Ejemplares similares
-
Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial
por: Zhao, Shuang, et al.
Publicado: (2020) -
Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
por: Zhu, Feng‐cai, et al.
Publicado: (2016) -
Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial
por: Zhu, Feng‐Cai, et al.
Publicado: (2019) -
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014) -
Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study
por: Hu, Yuemei, et al.
Publicado: (2020)